Merck Acquires OncoEthix

19.12.2014 11:21

Related tags

Merck, known as MSD outside the United States and Canada, announced today that it has acquired, through a subsidiary, OncoEthix, a Lausanne-based privately held biotechnology company specializing in oncology drug development. Financial terms of the acquisition include an upfront payment of up to $110 million to OncoEthix.

“Oncology is a priority area of focus for Merck and the acquisition of OncoEthix supports our strategy to prioritize the development of innovative molecules with the potential to improve the treatment of advanced cancers,” said Roy Baynes, senior vice president, global clinical development, Merck Research Laboratories. “The potential first-in-class oral BET inhibitor, OTX015, has demonstrated early promising activity in hematological cancers and strategically complements our broad immuno-oncology development program.”

“We are delighted that OTX015 will now be in the hands of Merck, a company with a successful track record of developing cutting-edge therapies,” said Bertrand Damour, chief executive officer, OncoEthix. “The acquisition underlines the promise that OTX015 has shown in the treatment of hematological malignancies, and the potential it has for the treatment of advanced solid tumors. We are confident that our transaction with Merck best positions OTX015 to be developed to its full potential in areas of high unmet medical need.”

BET proteins are considered potential therapeutic targets in cancer, as they play a pivotal role in regulating the transcription of key regulators of cancer cell growth and survival, including c-Myc. Interim data from ongoing Phase I clinical studies of OTX015 have demonstrated meaningful clinical activity in patients with hematological malignancies. Interim data were recently presented at the American Association of Cancer Research (AACR) Annual Meeting in April 2014. An international, open-label Phase 1 study evaluating OTX015 in five different solid tumors was initiated in November 2014.

Financial terms of the acquisition include an upfront payment of up to $110 million to OncoEthix. Additional milestone payments of up to $265 million are contingent upon certain clinical and regulatory events being achieved.

About OncoEthix
Founded in 2009, OncoEthix is a Swiss-based privately held biotechnology company aiming to develop a small portfolio of oncology drug candidates. The Company’s lead product, OTX015, is an investigational orally administered synthetic small molecule targeted to BET bromodomain proteins 2/3/4. OTX015 was in-licensed from Mitsubishi Tanabe Pharma Corporation in March 2012 following completion of Phase I clinical studies in healthy volunteers. OncoEthix has raised a total of US$30 million in venture capital to date: investors include Index Ventures, SV Life Sciences, Endeavour Vision and Edmond de Rothschild Investment Partners.

Comments

Please login or sign up to comment. Commenting guidelines

Principal

Partners

Contributors